PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 29 filers reported holding PHARVARIS N V in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,413,670 | +92.8% | 1,361,460 | +39.8% | 1.66% | +100.6% |
| Q2 2023 | $14,740,516 | +224022.2% | 973,614 | +19.2% | 0.83% | +90.8% |
| Q1 2023 | $6,577 | -28.4% | 816,460 | 0.0% | 0.43% | -29.6% |
| Q4 2022 | $9,185 | -99.9% | 816,460 | -32.4% | 0.62% | -4.9% |
| Q3 2022 | $9,262,000 | -63.4% | 1,207,500 | +5.4% | 0.65% | -66.2% |
| Q2 2022 | $25,326,000 | +103.9% | 1,145,953 | +67.3% | 1.92% | +100.7% |
| Q1 2022 | $12,420,000 | +25.1% | 684,888 | -0.7% | 0.95% | +61.7% |
| Q4 2021 | $9,925,000 | -18.8% | 689,731 | 0.0% | 0.59% | +18.7% |
| Q3 2021 | $12,229,000 | -10.3% | 689,731 | -7.4% | 0.50% | +7.3% |
| Q2 2021 | $13,634,000 | -42.7% | 744,863 | -13.8% | 0.46% | -12.6% |
| Q1 2021 | $23,811,000 | – | 864,143 | – | 0.53% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,261,926 | $60,770,000 | 8.21% |
| venBio Partners LLC | 2,303,310 | $42,911,000 | 5.06% |
| Bain Capital Life Sciences Investors, LLC | 3,180,601 | $59,255,000 | 3.88% |
| Foresite Capital Management V, LLC | 364,142 | $6,784,000 | 2.67% |
| VR Adviser, LLC | 902,882 | $16,821,000 | 2.04% |
| Cormorant Asset Management, LP | 744,863 | $13,634,000 | 0.46% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,032,757 | $19,240,000 | 0.34% |
| GENERAL ATLANTIC, L.P. | 2,420,155 | $45,087,000 | 0.32% |
| Opaleye Management Inc. | 79,837 | $1,487,000 | 0.25% |
| Avidity Partners Management LP | 400,000 | $7,452,000 | 0.20% |